Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-06-30 View official record Methodology

Covered recipient · General Payments record

THOMAS K OBRIEN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1952322588
CMS profile
133385
Location
TOMS RIVER, NJ

General Payments · PY2019–2025

$14,644.39

  • Reported across 666 records
  • CMS publication 2026-06-30

Latest program year · PY2025

$562.59

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2025 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $562.59 14

By paying entity

PY2025 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $306.19 5
Novo Nordisk AS $137.75 2
PFIZER INC. $69.36 4
Sumitomo Pharma America, Inc. $18.35 1
Lilly USA, LLC $16.49 1
LNHC, Inc $14.45 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,393.96 133
PY2020 $2,083.83 140
PY2021 $3,023.94 157
PY2022 $2,666.67 114
PY2023 $2,251.27 68
PY2024 $1,662.13 40
PY2025 $562.59 14

Payment records · PY2025 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2025 201920202021202220232024 Record-level detail is published for PY2025; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AstraZeneca Pharmaceuticals LP $47.83 07/08/2025 Food and Beverage Undisputed 06/30/2026 1206461059 CMS
AstraZeneca Pharmaceuticals LP $14.71 08/14/2025 Food and Beverage Undisputed 06/30/2026 1206399003 CMS
AstraZeneca Pharmaceuticals LP $103.46 09/25/2025 Food and Beverage Undisputed 06/30/2026 1206173144 CMS
AstraZeneca Pharmaceuticals LP $125.00 11/12/2025 Food and Beverage Undisputed 06/30/2026 1206661263 CMS
AstraZeneca Pharmaceuticals LP $15.19 11/20/2025 Food and Beverage Undisputed 06/30/2026 1206491128 CMS
Lilly USA, LLC $16.49 08/12/2025 Food and Beverage Undisputed 06/30/2026 1186927096 CMS
LNHC, Inc $14.45 12/02/2025 Food and Beverage Undisputed 06/30/2026 1242604024 CMS
Novo Nordisk Inc $12.74 08/27/2025 Food and Beverage Undisputed 06/30/2026 1189057687 CMS
Novo Nordisk Inc $125.01 10/30/2025 Food and Beverage Undisputed 06/30/2026 1188690288 CMS
PFIZER INC. $17.69 06/26/2025 Food and Beverage Undisputed 06/30/2026 1228907685 CMS
PFIZER INC. $17.43 08/27/2025 Food and Beverage Undisputed 06/30/2026 1229348516 CMS
PFIZER INC. $17.18 10/07/2025 Food and Beverage Undisputed 06/30/2026 1229143818 CMS
PFIZER INC. $17.06 12/16/2025 Food and Beverage Undisputed 06/30/2026 1229381062 CMS
Sumitomo Pharma America, Inc. $18.35 12/04/2025 Food and Beverage Undisputed 06/30/2026 1176699347 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.